SearchResearch
Beta
Hello! Describe your research question and I'll help you find matching datasets across 2,944 studies from AnVIL, BDC, CRDC, and KFDRC.

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Request Access

Effects of intensive glucose lowering in type 2 diabetes.

H. Gerstein, Michael E. Miller, R. Byington, et al. (2008). The New England journal of medicine. Cited 4,919 times. https://doi.org/10.1056/NEJMoa0802743

Effects of combination lipid therapy in type 2 diabetes mellitus.

H. Ginsberg, M. Elam, L. Lovato, et al. (2010). The New England journal of medicine. Cited 2,663 times. https://doi.org/10.1056/NEJMoa1001282

Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods.

J. Buse, J. Bigger, R. Byington, et al. (2007). The American journal of cardiology. Cited 627 times. https://doi.org/10.1016/J.AMJCARD.2007.03.003

Effects of intensive blood-pressure control in type 2 diabetes mellitus.

William C. Cushman, Gregory W Evans, R. Byington, et al. (2010). The New England journal of medicine. Cited 620 times. https://doi.org/10.1056/NEJMoa1001286

Variation in the Glucose Transporter gene SLC2A2 is associated with glycaemic response to metformin

K. Zhou, S. Yee, E. Seiser, et al. (2016). Nature genetics. Cited 193 times. https://doi.org/10.1038/ng.3632

Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial

Hetal S. Shah, He Gao, M. Morieri, et al. (2016). Diabetes Care. Cited 49 times. https://doi.org/10.2337/dc16-0285

A genome-wide study of lipid response to fenofibrate in Caucasians: a combined analysis of the GOLDN and ACCORD studies

M. Irvin, D. Rotroff, S. Aslibekyan, et al. (2016). Pharmacogenetics and Genomics. Cited 13 times. https://doi.org/10.1097/FPC.0000000000000219

Common and rare genetic markers of lipid variation in subjects with type 2 diabetes from the ACCORD clinical trial

Skylar W. Marvel, D. Rotroff, M. Wagner, et al. (2017). PeerJ. Cited 13 times. https://doi.org/10.7717/peerj.3187

Variants in ANGPTL4 and the Risk of Coronary Artery Disease.

M. Morieri, Hetal S. Shah, A. Doria. (2016). The New England journal of medicine. Cited 6 times. https://doi.org/10.1056/NEJMc1607380

Characteristics associated with informed consent for genetic studies in the ACCORD trial.

D. Simons-Morton, Jeffrey C Chan, A. Kimel, et al. (2014). Contemporary clinical trials. Cited 5 times. https://doi.org/10.1016/j.cct.2013.12.002

Incorporating Concomitant Medications into Genome-Wide Analyses for the Study of Complex Disease and Drug Response

H. Graham, D. Rotroff, Skylar W. Marvel, et al. (2016). Frontiers in Genetics. Cited 3 times. https://doi.org/10.3389/fgene.2016.00138